Fresenius Medical Care AG/€FME

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Fresenius Medical Care AG

Fresenius Medical Care, listed under the ticker FME, is a global provider of dialysis services and products for individuals diagnosed with chronic kidney failure. Founded in 1996 and headquartered in Bad Homburg, Germany, the company operates in the healthcare sector. Beyond dialysis, Fresenius Medical Care offers a range of other services, including hospital management and related healthcare services, advancing its position as a comprehensive healthcare provider internationally.

Ticker

€FME

Primary listing

XETRA

Industry

Health Care Providers & Services

Employees

112,035

ISIN

DE0005785802

FME Metrics

BasicAdvanced
€14B
21.90
€2.11
0.83
€1.44
3.12%

What the Analysts think about FME

Analyst ratings (Buy, Hold, Sell) for Fresenius Medical Care AG stock.

Bulls say / Bears say

Fresenius Medical Care reported stronger-than-expected first-quarter 2025 results, with revenues of €4.88 billion and adjusted operating income of €457 million, surpassing analysts' estimates. (reuters.com)
The company confirmed its 2025 outlook, anticipating U.S. market treatment growth to exceed 0.5% for the year, indicating confidence in future performance. (reuters.com)
Fresenius Medical Care's net income more than doubled in the first quarter of 2025, reaching €151 million, reflecting significant profitability improvements. (prnewswire.com)
The United Food and Commercial Workers Local 1776 health benefits fund filed a class action lawsuit against Fresenius Medical Care, alleging anti-competitive practices that inflated dialysis treatment costs. (reuters.com)
Fresenius Medical Care reduced its outlook for U.S. treatment volumes, now expecting flat to 0.5% growth, down from the previous 0.5% to 2% growth forecast, due to elevated patient mortality rates. (usnews.com)
Fresenius SE sold part of its stake in Fresenius Medical Care, reducing its ownership from 32.2% to 25% plus one share, leading to a 7.8% drop in FMC's stock price. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

FME Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

FME Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €FME

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs